Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1Chondrosarcoma 1

Interventions

Rituximab 57Cyclophosphamide 40Vincristine 26Prednisone 25Doxorubicin 22Cytarabine 18Lenalidomide 17Etoposide 17Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8zanubrutinib 7Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7R-CHOP protocol 6fludarabine phosphate 5Vindesine 5Radiotherapy 5Dexamethasone 5Decitabine 5Busulfan 5ibrutinib 4Methylprednisolone 4Epirubicin 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × TQ-B3525 × Clear all
NCT04610970 2021-08-18

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
93 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡